Find a Clinical Trial

Showing 11 - 20 of 182 Trials

AGCT1531 - A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Principal Investigator:

Nobuko Hijiya, MD

Contact Number:

212-342-5162

NCT Number:

NCT03067181

Population:

Pediatrics/Adult

Phase:

III

This partially randomized phase III trial studies how well active surveillance, bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and adult patients with germ cell tumors. Active surveillance may help doctors to monitor subjects with low risk germ cell tumors after their tumor is removed. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Are you Eligible? (Inclusion Criteria)...
ANBL1531, A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or AlK Inhibitor Therapy Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Principal Investigator:

Nobuko Hijiya, MD

Contact Number:

212-342-5162

NCT Number:

NCT03126916

Population:

Pediatrics/Adult

Phase:

III

This randomized clinical trial is examining whether the addition of radio- labelled MIBG or Crizotinib will improve the survival of high risk Neuroblastoma patients, as compared to standard treatment. Patients will be non-randomly assigned to Crizotinib based on tumor testing. All other patients will be randomized to receive standard therapy or standard therapy + MIBG. Are you Eligible? (Inclusion Criteria) Between 1 and 30 years of age Have a diagnosis of High Risk Neuroblastoma Enrolled on ANBL00B1 Patients must also meet all other eligibility criteria as outlined in the study
AAML1831: A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations

Principal Investigator:

Nobuko Hijiya, MD

Contact Number:

212-342-5162

NCT Number:

NCT04293562

Population:

Pediatrics

Phase:

III

This is a Phase 3 trial that will compare the efficacy of CPX-351 (a combination of 2 standard chemotherapy medicines - Daunorubicin and Cytarabine) compared to standard chemotherapy in the treatment of Acute Myelogenous Leukemia (AML). Patients will be randomly assigned by a computer to receive treatment with either CPX-351 treatment regimen or the standard chemotherapy regimen. In addition, if testing shows that a patient's AML has a specific gene change (FLT3), then those patients will be offered treatment with a new medicine (Gilteritinib) that targets the FLT3 gene change. For all...
A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma

Principal Investigator:

Fabio M. Iwamoto, MD

Contact Number:

212-342-5162

NCT Number:

NCT05095376

Population:

Adult

Phase:

III

The purpose of this study is to compare the usual radiation therapy and usual chemotherapy, temozolomide, to using the usual radiation therapy and usual chemotherapy plus the chemotherapy drug lomustine (Gleostine). Lomustine (Gleostine) is already approved by the FDA for use in brain tumors but it is usually used alone and is not the first-line choice for methylated MGMT tumors. Adding a second chemotherapy drug, lomustine (Gleostine), to usual chemotherapy and radiation therapy could extend your life or shrink or stabilize your cancer. But, it could also cause side effects, which the study...
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative

Principal Investigator:

Julia E McGuinness, MD

Contact Number:

212-342-5162

NCT Number:

NCT05232916

Population:

Adult

Phase:

III

The purpose of this research is to test how well an investigational study drug (medication), GLSI-100, can prevent your cancer from coming back. The research study will also collect information about the safety of the medication. The research will also study how the medication works and who responds the best to the medication. GLSI-100 is a combination of a study medication called GP2 and the FDA-approved medication, granulocyte-macrophage colony-stimulating factor (GM-CSF) or sargramostim (Leukine®). It is thought that this medication will work by helping your immune system identify and...
An Adaptive Phase 3, Randomized, Open-Label,Multicenter Study to Compare the Efficacy and Safety ofAxicabtagene Ciloleucel versus Standard of Care Therapy asFirst-Line Therapy in Subjects with High-Risk Large B-CellLymphoma (ZUMA-23)

Principal Investigator:

Ran Reshef, MD, MSc

Contact Number:

212-342-5162

NCT Number:

NCT05605899

Population:

Adult

Phase:

III

The purpose of this study is to find out if the experimental product, axi-cel, is safe and effective in treating your lymphoma, compared to standard of care (SOC) therapy (chemotherapy), which includes either R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone) or DA EPOCH R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab). The experimental treatment would involve removing some of your immune cells, genetically engineering those cells to identify cancer, receiving additional therapy while you wait for those cells to...
A Multinational, Multicenter, Prospective, OpenLabel, Safety and DosimetryStudy of Lutetium (177Lu)Rosopatamab Tetraxetan in Combination withStandard of Care in Patients with Prostate-SpecificMembrane Antigen (PSMA) Positive MetastaticCastration-Resistant

Principal Investigator:

Mark N. Stein, MD

Contact Number:

212-342-5162

NCT Number:

NCT06520345

Population:

Adult

Phase:

III

This study aims to explore a possible new treatment for advanced prostate cancer that has spread to other parts of the body and tests positive for a specific protein called PSMA (prostate-specific membrane antigen). This treatment involves a special drug that seeks out cancer cells by recognizing PSMA on their surface. The drug combines an antibody— a molecule that can find and attach to specific targets on cancer cells—with a radioactive component. Once attached, it delivers radiation directly to the cancer cells to help destroy them. The drug being studied is called 177Lu-TLX591...
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma

Principal Investigator:

Brian Peter Marr, MD

Contact Number:

212-342-5162

NCT Number:

NCT06007690

Population:

Adult

Phase:

III

The purpose of this study is to test and determine how safe and how well bel-sar treatment works compared to sham (no medication or laser) in participants who have a type of eye cancer called an indeterminate lesion (a growth in your eye that is suspected to be melanoma) or choroidal melanoma, also known as eye melanoma. We hope that Bel-sar can selectively target and destroy the tumor cells in the eye, while not affecting the normal cells. Bel-sar has not been approved by Food and Drug Administration (FDA). Are you Eligible? (Inclusion Criteria) must be 18 years old or older - must not have...
A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) after Imatinib Therapy (StrateGIST 3)

Principal Investigator:

Lanyi Nora Chen, MD

Contact Number:

212-342-5162

NCT Number:

NCT07218926

Population:

Adult

Phase:

III

Subjects are being asked to participate in this study because they have advanced gastrointestinal stromal tumor (GIST) that has spread to other parts of their body beyond where the cancer was first detected and/or cannot be removed by surgery, and because they experienced worsening of disease or side effects while taking an anti-cancer drug called imatinib. The purpose of this study is to test if IDRX-42 can improve GIST, enhance wellbeing, and be safe and well-tolerated when compared to sunitinib. People who usually have this can be prescribed sunitinib for their cancer. IDRX-42 and...
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy andSafety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants withResected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer -

Principal Investigator:

Benjamin Herzberg, MD

Contact Number:

212-342-5162

NCT Number:

NCT06890598

Population:

Adult

Phase:

III

The purpose of this research study is to learn more about a new medicine called olomorasib, to see if it can help treat lung cancer. We want to see if olomorasib, when used along with standard immunotherapy (pembrolizumab or durvalumab), works well for people with a certain type of lung cancer called KRAS G12C-mutated non-small cell lung cancer (NSCLC) after they’ve had their first treatment. In this study, some people will get olomorasib, and others will get a placebo. Olomorasib is the investigational study drug in this study, and it is not approved by the United States Food and Drug...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages